insights_auto
Why is RARE up 2.30%?
Dive Deeperchevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
$16.26
arrow_upward
+2.30%(+0.36) 1D
Nov 17, 12:52:13 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Open
$15.94
High
$16.56
Low
$15.65
Mkt. cap
1.66B
Avg. vol.
3.65M
Volume
1.61M
52-wk high
$39.89
52-wk low
$12.73
EPS
-$5.19
Beta
0.37
Shares outstanding
101.92M
No. of employees
1K
Open
$15.94
High
$16.56
Low
$15.65
Mkt. cap
1.66B
Avg. vol.
3.65M
Volume
1.61M
52-wk high
$39.89
52-wk low
$12.73
EPS
-$5.19
Beta
0.37
Shares outstanding
101.92M
No. of employees
1K
News stories
From web sources and news partners
Investing.com
·
3 hours ago
Ultragenyx at Jefferies Global Healthcare Conference: profit path in focus
Investing.com Canada
·
1 day ago
Ultragenyx at UBS biopharma conference: growth plan after setbacks By Investing.com
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1.37K
Founded2010
HeadquartersNovato, California, United States
SectorHealth Care
IndustryBiotechnology
Websiteultragenyx.com
Analyst ratings
Based on 21 analysts giving stock ratings to RARE in the past 3 months
Buy
Buy
10
Hold
11
Sell
0
12-month forecast
Based on 21 Wall Street analysts offering 12 month price targets for RARE in the last 3 months.
Highest
Current $16.26
$39.00 (+139.78%)
Average
$24.85 (+52.78%)
Lowest
$16.00 (-1.63%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Debjit Chattopadhyay Guggenheim | Buy | Reiterated | $24.00 | +47.6% | 11/16/2026 |
Maxwell Skor Morgan Stanley | Hold | Maintained | $22.00 | +35.3% | 11/16/2026 |
Yigal Nochomovitz Citi | Buy | Maintained | $22.00 | +35.3% | 11/06/2026 |
Joseph Schwartz Leerink Partners | Buy | Reiterated | $33.00 | +102.9% | 11/05/2026 |
Allison Bratzel Piper Sandler | Buy | Maintained | $36.00 | +121.3% | 11/05/2026 |
Ram Selvaraju H.C. Wainwright | Buy | Reiterated | $25.00 | +53.7% | 11/06/2026 |
Eliana Merle Barclays | Buy | Maintained | $32.00 | +96.7% | 11/05/2026 |
Kristen Kluska Cantor Fitzgerald | Buy | Maintained | $39.00 | +139.8% | 11/03/2026 |
Yaron Werber TD Cowen | Buy | Maintained | $19.00 | +16.8% | 11/04/2026 |
Luca Issi RBC Capital | Hold | Maintained | $19.00 | +16.8% | 11/04/2026 |
Laura Chico Wedbush | Hold | Maintained | $22.00 | +35.3% | 11/04/2026 |
Whitney Ijem Canaccord Genuity | Buy | Maintained | $34.00 | +109% | 11/04/2026 |
Benjamin Burnett Wells Fargo | Hold | Maintained | $19.00 | +16.8% | 11/03/2026 |
Salveen Richter Goldman Sachs | Hold | Maintained | $17.00 | +4.5% | 11/04/2026 |
Tazeen Ahmad Bank of America Securities | Hold | Reiterated | $20.00 | +23% | 11/04/2026 |
Joon Lee UBS | Hold | Initiated | $16.00 | -1.6% | 10/14/2026 |
Gavin Clark-Gartner Evercore ISI | Hold | Maintained | $18.00 | +10.7% | 09/21/2026 |
Sami Corwin William Blair | Hold | Maintained | - | - | 09/18/2026 |
Maury Raycroft Jefferies | Buy | Maintained | $28.00 | +72.1% | 09/03/2026 |
Anupam Rama J.P. Morgan | Hold | Downgraded | $36.00 | +121.3% | 09/03/2026 |
Jack Allen Robert W. Baird | Hold | Downgraded | $16.00 | -1.6% | 09/03/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $77.00 | +373.4% | 08/21/2026 |
Unknown Analyst Wedbush | Hold | Maintained | $30.00 | +84.4% | 08/20/2026 |
Last report
Nov 4, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
-$1.16 / -$0.75
-54.39%miss
arrow_downward
Revenue / Est. (USD)
173.00M / 183.71M
-5.83%miss
arrow_downward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 207.28M | 136.00M | 214.00M | 173.00M |
Cost of goods sold | 232.62M | 189.00M | 201.00M | 186.00M |
Cost of revenue | 232.62M | 189.00M | 201.00M | 186.00M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 87.94M | 86.00M | 88.00M | 97.00M |
Operating expense | 87.94M | 86.00M | 88.00M | 97.00M |
Total operating expenses | 320.56M | 275.00M | 289.00M | 283.00M |
Operating income | -113.28M | -139.00M | -75.00M | -110.00M |
Other non operating income | -934.00K | - | 1.00M | - |
EBT including unusual items | -127.69M | -184.00M | -91.00M | -127.00M |
EBT excluding unusual items | -127.17M | -154.00M | -91.00M | -127.00M |
Income tax expense | 870.00K | 1.00M | 1.00M | -9.00M |
Effective tax rate | -0.68% | -0.54% | -1.10% | 7.09% |
Other operating expenses | - | - | - | - |
Net income | -128.56M | -185.00M | -92.00M | -118.00M |
Net profit margin | -62.02% | -136.03% | -42.99% | -68.21% |
Earnings per share | -1.29 | -1.54 | -0.90 | -1.16 |
Interest and investment income | 6.51M | 6.00M | 5.00M | 3.00M |
Interest expense | -19.47M | -21.00M | -22.00M | -20.00M |
Net interest expenses | -12.96M | -15.00M | -17.00M | -17.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -104.50M | -131.00M | -67.00M | -101.00M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events